CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)

CD123/CLL1 CAR-T Cell Therapy for Relapsed and Refractory Acute Myeloid Leukemia

Status

UNKNOWN

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03631576

Enrollment

Registered

2018-08-15

Start date

2018-08-10

Completion date

2021-08-10

Last updated

2020-01-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed/Refractory AML

Brief summary

The treatment options for relapse/refractory B-cell acute myeloid leukemia(AML)are limited.CD123/CLL1 CAR-T Cells may have a permanent anti-tumor effect and became very attractive. This study aims to assess the safety and toxicity of CD123/CLL1 CAR-T Cells to patients with relapse/refractory AML.

Interventions

BIOLOGICALCD123/CLL1 CAR-T Cells

CD123/CLL1 CAR-T Cell Therapy

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

No minimum to 70 Years

Healthy volunteers

Inclusion criteria

* Signed written informed consent * Aged \< 70 years * Patients with relapsed/refractory AML * Cardiac: Left ventricular ejection fraction ≥ 50% * Adequate renal and hepatic function * Performance status: Karnofsky ≥ 70%

Exclusion criteria

* Pregnant or lactating females. * Any co-morbidity precluding the administration of CD123/CLL1 CAR-T Cells.

Design outcomes

Primary

Measure	Time frame
Leukemia free survival	1 year

Secondary

Measure	Time frame
Adverse events that are related to treatment	1 year

Countries

China

Contacts

Primary ContactJianda Hu, Prof.M.D.Ph.D

drjiandahu@163.com86-13959169016

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026